Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction

被引:7
作者
Prebet, Thomas [1 ]
Jean, Estelle [1 ,4 ]
Autret, Aurelie [2 ]
Charbonnier, Aude [1 ]
Rey, Jerome [1 ]
Etienne, Anne [1 ]
D'incan, Evelyne [1 ]
Fuerst, Sabine [1 ]
Arnoulet, Christine [3 ]
Blaise, Didier [1 ,4 ]
Vey, Norbert [1 ,4 ]
机构
[1] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[2] Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France
[3] Inst J Paoli I Calmettes, Dept Biopathol, F-13009 Marseille, France
[4] Aix Marseille Univ, Fac Med, Marseille, France
关键词
Acute myeloid leukemia; topotecan; cytarabine; COOPERATIVE-ONCOLOGY-GROUP; MYELODYSPLASTIC SYNDROME; INTENSIVE CHEMOTHERAPY; COMPLETE REMISSION; REGIMENS; RECOMMENDATIONS; DIAGNOSIS; THERAPY; BLASTS; TRIALS;
D O I
10.3109/10428194.2012.685733
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
After a first course of induction chemotherapy, 30-40% of patients with acute myeloid leukemia (AML) do not achieve a complete response (CR). A second course of an anthracycline and intermediate-dose cytarabine (IDAC) allows a significant number of patients with persistent AML at day 14 to finally achieve a CR. We hypothesized that use of a topotecan and cytarabine combination in this setting might improve tolerance and efficacy. Cytarabine (1000 mg/m(2)/12 h days 1-4) was combined with topotecan (TA, 1.25 mg/m(2)/day by continuous intravenous infusion [CIV] days 1-4) in 31 consecutive patients with >= 5% marrow blasts by day 14 of induction. The median follow-up was 36 months. The CR rate was 81%, and the 2-year probability of overall survival and cumulative incidence of relapse were 66% and 38%, respectively. No unexpected toxicity was observed. Comparison with historical controls treated with the combination of a similar schedule of cytarabine and an anthracycline showed a better CR rate (p = 0.054), overall survival (p = 0.03) and cumulative incidence of relapse (p = 0.03). These results were confirmed in a multivariate analysis model. This work shows that the substitution of an anthracycline by topotecan is feasible and associated with significant efficacy for patients with AML with persistent leukemia at day 14 after standard-dose anthracycline induction.
引用
收藏
页码:2186 / 2191
页数:6
相关论文
共 50 条
[41]   High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML) [J].
Larson, Sarah M. ;
Campbell, Nicholas P. ;
Huo, Dezheng ;
Artz, Andrew ;
Zhang, Yanming ;
Gajria, Devika ;
Green, Margaret ;
Weiner, Howie ;
Daugherty, Christopher ;
Odenike, Olatoyosi ;
Godley, Lucy A. ;
Hyjek, Elizabeth ;
Gurbuxani, Sandeep ;
Thirman, Michael ;
Sipkins, Dorothy ;
Van Besien, Koen ;
Larson, Richard A. ;
Stock, Wendy .
LEUKEMIA & LYMPHOMA, 2012, 53 (03) :445-450
[42]   Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia [J].
Trifilio, Steven M. ;
Rademaker, Alfred W. ;
Newman, Diane ;
Coyle, Katherine ;
Carlson-Leuer, Katrin ;
Mehta, Jayesh ;
Altman, Jessica ;
Frankfurt, Olga ;
Tallman, Martin S. .
LEUKEMIA RESEARCH, 2012, 36 (04) :394-396
[43]   A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy [J].
Kim, Dae-Young ;
Lee, Je-Hwan ;
Sym, Sun Jin ;
Yun, Sung-Cheol ;
Lee, Jung-Hee ;
Kim, Sung-Doo ;
Choi, Yunsuk ;
Lee, Young-Shin ;
Kang, Young-Ah ;
Jeon, Mijin ;
Seol, Miee ;
Lee, Kyung-Hwa ;
Lee, Yeon-Joo ;
Lee, Kyoo-Hyung .
ANNALS OF HEMATOLOGY, 2011, 90 (11) :1283-1291
[44]   Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy [J].
Boyiadzis, Michael ;
Redner, Robert L. ;
Raptis, Anastasios ;
Hou, Jing-Zhou ;
Agha, Mounzer ;
Foon, Kenneth A. .
ANNALS OF HEMATOLOGY, 2011, 90 (06) :733-735
[45]   Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia [J].
Ferrara, Felicetto ;
D'Arco, Alfonso M. ;
De Simone, Mariacarla ;
Mele, Giuseppina ;
Califano, Catello ;
Pocali, Barbara ;
Danise, Paolo ;
Palmieri, Salvatore .
HAEMATOLOGICA, 2005, 90 (06) :776-784
[46]   Intensively Timed Combination Chemotherapy for the Induction of Adult Patients With Acute Myeloid Leukemia [J].
Rytting, Michael ;
Ravandi, Farhad ;
Estey, Elihu ;
Cortes, Jorge ;
Faderl, Stefan ;
Garcia-Manero, Guillermo ;
Jeha, Sima ;
Ouzounian, Souzanne ;
Pierce, Sherry ;
Kantarjian, Hagop .
CANCER, 2010, 116 (22) :5272-5278
[47]   Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia [J].
Chen, Chen ;
Xu, Wei ;
Yang, Jing .
LEUKEMIA & LYMPHOMA, 2015, 56 (01) :141-146
[48]   Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols [J].
Tomizawa, Daisuke ;
Watanabe, Tomoyuki ;
Hanada, Ryoji ;
Horibe, Keizo ;
Horikoshi, Yasuo ;
Iwamoto, Shotaro ;
Kinoshita, Akitoshi ;
Moritake, Hiroshi ;
Nakayama, Hideki ;
Shimada, Akira ;
Taga, Takashi ;
Takahashi, Hiroyuki ;
Tawa, Akio ;
Terui, Kiminori ;
Hori, Hiroki ;
Kawano, Yoshifumi ;
Kikuta, Atsushi ;
Manabe, Atsushi ;
Adachi, Souichi .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 102 (03) :318-326
[49]   Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy [J].
Rodriguez-Macias, Gabriela ;
Briz, Oscar ;
Cives-Losada, Candela ;
Chillon, Maria C. ;
Martinez-Laperche, Carolina ;
Martinez-Arranz, Ibon ;
Buno, Ismael ;
Gonzalez-Diaz, Marcos ;
Diez-Martin, Jose L. ;
Marin, Jose J. G. ;
Macias, Rocio I. R. .
CANCERS, 2023, 15 (12)
[50]   High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years [J].
Arellano, Martha ;
Winton, Elliott ;
Pan, Lin ;
Lima, Lisa ;
Tighiouart, Mourad ;
Bhalla, Kapil ;
Heffner, Leonard T. ;
Neely, Jessica ;
Hutcherson, Donald ;
McLemore, Morgan ;
Langston, Amelia ;
Khoury, H. Jean .
CANCER, 2012, 118 (02) :428-433